Efficacy and safety of TAF in older patients with CHB from China

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000034699

Enrollment

Unknown

Registered

2020-07-15

Start date

2020-08-01

Completion date

Unknown

Last updated

2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

CHB group:treatment with TAF

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with CHB; 2. Aged > 60 year (with or without comorbidities including hypertension, diabetes, cardiovascular disease, osteoporosis, CKD and so on); Treatment naive or treatment experienced patients.

Exclusion criteria

Exclusion criteria: 1. Co-infection with HCV/HDV/HIV 2. Moribund state including advanced/pre-terminal liver cancer or other non-hepatic cancers; 3. Non-hepatic cancer undergoing chemotherapy within last 6 months

Design outcomes

Primary

Measure	Time frame
HBV DNA;ALT;DXA;eGFR;RBP;a1M;	—

Countries

China

Contacts

Public ContactXin Yongning

Qingdao Municipal Hospital

xinyongning@163.com+86 0532-82789463

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026